MRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method

Leukemia

Volumn 14, Issue 12, 2000, Pages 2166-2175

  Rots, M G ^a   Willey, J C ^b   Jansen, G ^a   Van Zantwijk, C H ^a   Noordhuis, P ^a   DeMuth, J P ^b   Kuiper, E ^a   Veerman, A J P ^a   Pieters, R ^a,c   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Childhood leukemia; Competitive template RT PCR; Dihydrofolate reductase; Methotrexate; Polyglutamylation; Reduced folate carrier

Indexed keywords

BETA ACTIN; DIHYDROFOLATE REDUCTASE; FOLYLPOLYGLUTAMATE SYNTHASE; GAMMA GLUTAMYL HYDROLASE; MESSENGER RNA; METHOTREXATE; REDUCED FOLATE CARRIER; THYMIDYLATE SYNTHASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANALYTIC METHOD; ARTICLE; CELL LINEAGE; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; NUCLEOTIDE SEQUENCE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STANDARDIZATION; T LYMPHOCYTE;

EID: 17744385728     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401943     Document Type: Article

References (61)

1. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
2. Acute lymphoblastic leukemia
3. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia
4. Maintenance chemotherapy and cure of childhood acute lymphoblastic leukaemia
5. Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay
6. Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro
7. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells
8. Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates
9. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression
10. The role of impaired transport in (pre)clinical resistance to methotrexate: Insights on new antifolates
11. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia
12. The role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia
13. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia
14. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo, a rational for high-dose methotrexate
15. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: A pilot prognostic factor analysis
16. Polyglutamation of methotrexate. Is methotrexate a prodrug?
17. Gamma-glutamyl hydrolase and folylpolyglutamate synthetase activities, predict polyglutamylation of methotrexate in acute leukemias
18. Intrinsic and acquired resistance to methotrexate in acute leukemia
19. A rapid and versatile method to synthesize internal standards for competitive PCR
20. Expression measurement of many genes simultaneously by quantitative RT-PCR using standardized mixtures of competitive templates
21. Quantitative RT-PCR measurement of cytochromes p450 1A1, 1B1, and 2B7, microsomal epoxide hydrolase, and NADPH oxidoreductase expression in lung cells of smokers and nonsmokers
22. Loss of sprl expression measurable by quantitative RT-PCR in human bronchogenic carcinoma cell lines
23. The gene expression index c-myc x E2F-1/p21 is highly predictive of malignant phenotype in human bronchial epithelial cells
24. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions
25. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay
26. Effects of methotrexate esters and other lipophilic antifolates on methotrexate-resistant human leukemic lymphoblasts
27. Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier
28. Receptor- and carrier-mediated transport systems for folates and antifolates
29. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance
30. Measurement of gene expression by multiplex competitive polymerase chain reaction
31. Normal bronchial epithelial cell expression of glutathione transferase P1, glutathione transferase M3, and gluthione peroxidase is low in subjects with bronchogenic carcinoma
32. Measurement of cytochrome P450 2A6 and 2E1 gene expression in primary human bronchial epithelial cells
33. Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer
34. Heterogeneity in the specific activity and methotrexate sensitivity of dihydrofolate reductase from blast cells of acute myelogenous leukemia patients
35. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction
36. Quantitative analysis of folypolyglutamate synthetase gene expression in tumor tissues by the polymerase chain reaction: Marked variation of expression among leukemia patients
37. Analysis of cytokine mRNA and DNA: Detection and quantitation by competitive polymerase chain reaction
38. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia-relationship to immunophenotype and ploidy
39. Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children
40. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia
41. Reduced folate carrier expression in acute lymphoblastic leukemia: A mechanism for ploidy but not for lineage differences in methotrexate accumulation
42. Natural resistance to methotrexate in human acute nonlymphocytic leukemia
43. A possible role for methotrexate in the treatment of childhood acute myeloid leukemia, especially of acute monocytic leukemia
44. Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins
45. Overexpression of p21waf1 leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells
46. Role of thymidylate synthetase activity in development of methotrexate cytotoxicity
47. Effect of direct suppression of thymidylate synthase at the 5, 10-methylenetetrahydrofolate binding site on the interconversion of tetrahydrofolate cofactors to dihydrofolate by antifolates
48. Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression
49. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer
50. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: Implications for treatment with fluorouracil
51. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin
52. Regulation of carrier-mediated transport of folates and anti-folates in methotrexate-sensitive and -resistant leukemia cells
53. Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line
54. Molecular mechanism of antifolate transport-deficiency in a methotrexate-resistant MOLT-3 human leukemia cell line
55. A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectively alters its interaction with folate analogues. Implications for intrinsic antifolate resistance and the transporter within the plasma membrane of tumor cells
56. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: Mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity
57. Decreased folylpolyglutamate synthetase expression: A novel mechanism of fluorouracil resistance
58. Different antifolate-resistant L1210 cell variants with either increased or decreased folylpolyglutamate synthetase gene expression at the level of mRNA transcription
59. Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure
60. Multifactorial resistance to 5, 10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM
61. Folylpolyglutamate synthetase expression in antifolate sensitive and-resistant human cell lines